Compare Natera Inc. Common Stock (NTRA) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Viking Holdings Ltd Ordinary Shares — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Viking Holdings Ltd Ordinary Shares trades at $82.22 (market cap $36.70B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Viking Holdings Ltd Ordinary Shares for 6 Days on average.
| NTRA | VIK | |
|---|---|---|
Market Cap | $57.03B | $36.70B |
Volume | 1,131,157 | 2,076,556 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $108.26 |
52-Week Low | $179.42 | $57.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $39.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Viking Holdings (VIK) trades at $82.16, up 1.72% on the day, with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue for 2025 reached $6.50 billion, with a net income margin of 19.33%, while analyst consensus is strongly bullish with an 86.66% buy rating and a $107.92 price target. Recent news highlights fleet expansion, a $1 billion share repurchase program, and premium positioning in luxury travel.
VIK presents a compelling growth opportunity driven by strong bookings, expanding fleet, and premium valuations, though risks include execution on capital expenditure and sensitivity to travel disruptions. The stock's current price near key support at $81 suggests potential for upward movement toward resistance levels, supported by positive institutional sentiment and operational cash flow strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Viking Holdings Ltd Ordinary Shares
Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →
